SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heavy buying and a sharp rebound have fueled speculation about a potential buyout or imminent company news, but neither has been confirmed. The main catalyst in discussion is the Phase 3 REGAL trials pending final analysis after the last disclosed count of 78 of 80 events; bullish traders read the CEOs optimistic anniversary post as encouraging, while skeptics point to the lack of new trial news and caution that the move may reflect trading activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound above recent technical levels has traders discussing a possible breakout and short covering, though no specific new catalyst is confirmed. Bulls are also anticipating DM1 and FSHD siRNA readouts, while some caution that the move may reflect broader biotech strength or prove temporary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs shares fell despite a third-quarter earnings beat and a new buyback, as traders focused on the narrowed full-year profit outlook and unchanged midpoint. The reaction is split between dip buyers citing cash generation and repurchases, and bears who see the outlook and softer sales as outweighing those positives.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly beat and raised 2026 outlook are being overshadowed by a sharp selloff. Traders debate whether it is a sell-the-news reaction after expectations ran high or a response to rising costs, weaker cash conversion and an insurance loss, while some point to strong orders as evidence demand remains robust.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in bipolar mania met its primary and secondary endpoints, fueling buying interest and analyst optimism. Traders are debating whether the efficacy signal is strong enough given the modest placebo-adjusted improvement, higher discontinuation rates, and safety questions, contributing to volatile trading.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention as traders watch for Q3 results to confirm continued growth in high-margin ASCENIV amid weakness in BIVIGAM, with the recent move around its 200-day average adding to the recovery discussion. Bulls point to ASCENIV and share repurchases, while skeptics cite uncertain growth and lingering concerns from the Culper short report and related litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DICK'S Sporting's Digital Expansion Strategy to Fuel Growth

DKS is accelerating digital growth through GameChanger, ScoreCard+ and its media network, boosting engagement, personalization and profitability.


Dick's Sporting Goods Class Action Reminder - Robbins LLP Encourages Investors to Contact the Firm for Information About Their Rights

Dick's Sporting Goods Class Action Reminder - Robbins LLP Encourages Investors to Contact the Firm for Information About Their Rights Dick's Sporting Goods Class Action Reminder - Robbins LLP Encourages Investors to Contact the Firm for Information About Their RightsPR NewswireSAN DIEGO, Oct. 19...

DKS Investors Have Opportunity to Lead DICK'S Sporting Goods, Inc. Securities Fraud Lawsuit with SBS Law

DKS Investors Have Opportunity to Lead DICK'S Sporting Goods, Inc. Securities Fraud Lawsuit with SBS Law DKS Investors Have Opportunity to Lead DICK'S Sporting Goods, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 19, 2026 LOS ANGELES, Oct. 19, 2026 /PRNewswire/ -- Schall...

1 Reason Dick's Sporting Goods Is Worth a Second Look This Month

Key PointsShares of Dick's Sporting Goods have tumbled recently due to excess footwear inventory and integration struggles with the Foot Locker buyout...

Dick's Sporting Goods (DKS) Outpaces Stock Market Gains: What You Should Know

Dick's Sporting Goods (DKS) closed the most recent trading day at $140.84, moving +2.83% from the previous trading session.

DKS Deadline: DKS Investors with Losses in Excess of $100K Have Opportunity to Lead DICK'S Sporting Goods, Inc. Securities Fraud Lawsuit

DKS Deadline: DKS Investors with Losses in Excess of $100K Have Opportunity to Lead DICK'S Sporting Goods, Inc. Securities Fraud Lawsuit DKS Deadline: DKS Investors with Losses in Excess of $100K Have Opportunity to Lead DICK'S Sporting Goods, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct...

SueWallSt Reminds DICK'S SPORTING GOODS, INC. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - DKS

SueWallSt Reminds DICK'S SPORTING GOODS, INC. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - DKS SueWallSt Reminds DICK'S SPORTING GOODS, INC. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - DKSPR...

DICK'S Sporting Goods Inc. to Hire Over 11,000 Seasonal Teammates for the 2026 Holiday Shopping Season

DICK'S Sporting Goods Inc. to Hire Over 11,000 Seasonal Teammates for the 2026 Holiday Shopping Season DICK'S Sporting Goods Inc. to Hire Over 11,000 Seasonal Teammates for the 2026 Holiday Shopping SeasonPR NewswirePITTSBURGH, Oct. 15, 2026PITTSBURGH, Oct. 15, 2026 /PRNewswire/ -- DICK'S (NYSE...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in DICK'S Sporting Goods, Inc. of Class Action Lawsuit and Upcoming Deadlines - DKS

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in DICK'S Sporting Goods, Inc. of Class Action Lawsuit and Upcoming Deadlines - DKS INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in DICK'S Sporting Goods, Inc. of Class...

DKS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in DICK'S SPORTING GOODS, INC. Securities Lawsuit - Contact Levi & Korsinsky

DKS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in DICK'S SPORTING GOODS, INC. Securities Lawsuit - Contact Levi & Korsinsky DKS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in DICK'S SPORTING GOODS, INC. Securities Lawsuit - Contact Levi...

Dick's Sporting Goods, Inc. engages in the retailing of an extensive assortment of authentic sports equipment, apparel, footwear, and accessories. It also offers its products both online and through mobile applications. The company was founded by Richard T. Stack in 1948 and is headquartered in Coraopolis, PA.

Dicks Sporting Goods, Inc.

NKE, FLNC, CPRT, ULTA, JBHT: Top Wall Street Calls And Target Changes Making Waves This Week

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Baird downgraded Nike, while UBS warned global growth has weakened, and earnings could miss estimates.</li><li>Fluence Energy shares fell over 22% this week after the company lowered fiscal 2026 revenue guidance to $2.4 billion from $3 billion.&nbsp;</li><li>Wells Fargo upgraded Ulta Beauty to Equal Weight and raised its price target to $525, citing momentum in the business.&nbsp;</li></ul><p>Wall Street analysts made notable moves across the consumer and industrial sectors this week, adjusting ratings and price targets for Nike Inc. (NKE), Ulta Beauty Inc. (ULTA), Copart Inc. (CPRT), Fluence Energy (FLNC) and J.B. Hunt Transport Services (JBHT). Analysts cited shifting consumer demand, industry pressures, company-specific execution and improving business trends as they reassessed the outlook for these stocks.&nbsp;</p><h2 class="st-heading-2">Nike Analysts Flag Weak Demand&nbsp;</h2><p><a href="https://stocktwits.com/symbol/NKE">Nike stock</a> fell over 1% this week and is on track for a fourth week of losses, trading at twelve-year lows as several analysts point to sluggish sales, promotional pressure and uncertainty surrounding the athleticwear giant’s turnaround.</p><p>Baird downgraded Nike to ‘Neutral’ from ‘Outperform’ and reduced its price target to $44 from $70. The firm said conditions across the active-lifestyle market have become less favorable heading into the fourth quarter. Baird still expects Nike’s long-term earnings potential to improve, but recent developments have increased concerns around the recovery.</p><p>UBS also trimmed its price target to $42 from $48 while maintaining a ‘Neutral’ rating. Based on its checks with retailers and other sales channels, UBS said Nike’s worldwide growth trajectory has weakened over the past three months. The firm expects the company to potentially miss its fiscal first-quarter 2027 earnings estimate by $0.05 per share.</p><p>On Stocktwits, retail sentiment for NKE shifted to ‘neutral’ from ‘bearish’.&nbsp;</p><h2 class="st-heading-2">Fluence Energy’s Guidance Cut Reflects Execution Risks&nbsp;</h2><p><a href="https://stocktwits.com/symbol/FLNC">Fluence Energy stock</a> has plunged over 22% this week, facing heightened pressure from Wall Street after the energy-storage company reduced its fiscal 2026 outlook to $2.4 billion from the previous $3 billion target.&nbsp;</p><p>Ben Kallo, an analyst at Baird, downgraded Fluence to ‘Underperform’ from ‘Neutral’ and cut his price target to $3 from $10. The analyst said production ramp-up problems in the U.S. prompted the company to lower its guidance.</p><p>Baird also highlighted management's comments about temporarily scaling back U.S. activity. Kallo described the developments as "material negatives" and said the firm has become "incrementally negative" on the company's prospects.</p><p>RBC Capital analyst Christopher Dendrinos also reduced his price target to $4 from $15 while maintaining a ‘Sector Perform’ rating, while BMO Capital slashed the price target to $7 from $14 while retaining a ‘Market Perform’ rating. However, retail sentiment improved to ‘extremely bullish’ from ‘bullish’ the previous day.&nbsp;</p><h2 class="st-heading-2">Ulta Beauty Gets Upgraded On Business Momentum&nbsp;</h2><p>Wells Fargo upgraded Ulta Beauty to ‘Equal Weight’ from ‘Underweight’ and raised its price target to $525 from $450 after a meeting with company management. The firm said the discussions provided greater confidence in Ulta’s ability to expand while navigating a difficult retail environment.</p><p>The analyst said Ulta’s leadership appeared confident about expanding the business. Wells Fargo also pointed to strategic changes under the company’s new management team as a potential source of improvement. The firm now sees a more balanced reward-to-risk profile at current levels.</p><p>Ulta ended its shop-in-shop partnership with Target (TGT) last month, bringing exclusive prestige beauty brands back to its own stores and platforms.&nbsp;<a href="https://stocktwits.com/symbol/ULTA">Ulta Beauty stock</a> edged 0.5% lower this week.&nbsp;</p><h2 class="st-heading-2">Copart’s Growth Story Hits A Speed Bump&nbsp;</h2><p>Copart stock is heading into a second week of losses, with analysts taking a more cautious outlook after pressure on U.S. insurance volumes. HSBC downgraded Copart to ‘Hold’ from ‘Buy’ and set a $36 price target. The firm said the company's prospects have become harder to navigate after its fiscal fourth quarter showed another steep drop in U.S. insurance-related volumes, while rival RB Global (RBA) performed differently.</p><p>HSBC also pointed to a slowdown in Copart’s selling prices. Stronger pricing had helped the company support revenue growth in recent periods, but the analyst now sees signs that this benefit may be fading. Freedom Broker also reduced its Copart price target, bringing it down to $36 from $39 while maintaining a Buy rating. Retail sentiment around the stock remained ‘bearish’.&nbsp;</p><h2 class="st-heading-2">Analysts Shift Views On Dick's And J.B. Hunt</h2><p>Baird downgraded Dick's Sporting Goods to ‘Neutral’ from ‘Outperform’ with a $150 price target, citing weak industry performance, economic pressure and uncertainty over consumer spending. Baird also sees investors facing a difficult recovery path as other parts of the economy offer stronger growth opportunities.&nbsp;</p><p>Citizens took the opposite approach with J.B. Hunt Transport Services, upgrading it to ‘Outperform’ from ‘Market Perform’ and setting a $300 price target, implying 26% upside from the stock’s last closing price. The upgrade follows an 18% decline in J.B. Hunt shares since the company reported Q2 results in July. Citizens believes that retreat has created a more favorable entry point.</p><p><a href="https://stocktwits.com/symbol/DKS">Dick's Sporting Goods stock</a> has dropped over 8% this week, while&nbsp;<a href="https://stocktwits.com/symbol/JBHT">J.B. Hunt Transport stock</a> is heading for its worst week in four years, with a 12% plunge.&nbsp;</p><p>So far this year, NKE, ULTA, FLNC, CPRT, and DKS stocks have declined between 10% and 61%, while JBHT stock has gained 21%.</p><p>Also see:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nasa-selects-space-x-for-star-burst-mission/cZtsPMARBdr">SPCX Stock Inches Higher After-Hours: NASA Selects SpaceX To Provide Launch Services For StarBurst Mission</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

A general view shows shoes at a Nike store in Guangzhou, Guangdong Province of China.

Analysts reassessed the stocks, citing weak demand, execution concerns, business momentum, and changing industry conditions.

Copart, Inc.

Fluence Energy Inc - Ordinary Shares - Class A

J.B. Hunt Transport Services, Inc.

Nike Inc

Ulta Beauty Inc

Yes, buying

No, staying away

Just holding what I have

Watching from the sidelines

Walmart ($WMT) is pulling back despite beating Q2 earnings estimates and raising full-year EPS guidance, as investors react to disappointing comparable sales growth and cautious Q3 commentary. Are you buying $WMT on the dip? Vote and explain your reasoning in the comments.

Walmart ($WMT) stock is down despite a Q2 earnings beat and raised full-year profit forecast. Are you buying the dip?

Stocktwits

Walmart Inc

) stock is down despite a Q2 earnings beat and raised full-year profit forecast. Are you buying the dip?

Current Price	$143.70
Prev Close	$143.77
Open	$144.50
Dividend Yield	2.40%
50-Day Moving Average	$147.12
Beta	1.24
Avg. Volume	3.12M
PE Ratio	15.44

52-Week High	$244.38
52-Week Low	$120.15
Market Capitalization	$12.79B
EPS (Annual)	$9.97
Price to Book	2.24
Revenue Per Employee	$163,641.83

Feed

News

Sentiment

Earnings

Fundamentals

Info

DKS Fundamentals